Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H-6
- Development stage
- Phase 1
- Lead developer
- Shifa Biomedical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
H-6 is a discovery-stage small molecule inhibitor developed by Shifa Biomedical for the treatment of dyslipidemia. It targets Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) by binding to the protein's surface at the site where the Epidermal Growth Factor-like domain A (EGF(A)) of the Low-Density Lipoprotein Receptor (LDLR) typically attaches. By inhibiting the PCSK9-LDLR interaction, H-6 prevents the lysosomal degradation of LDLR, thereby increasing the density of LDLR on the surface of hepatocytes and facilitating the clearance of LDL cholesterol from the bloodstream.
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on H-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H-6.